Strategic Initiatives

The outpouring of support from the ALS Ice Bucket Challenge has allowed the ALS Association to champion numerous new strategic initiatives in order to build understanding of the disease, target new therapies, expedite clinical trials and make RNA and DNA sequencing data available for the entire ALS research community. These collaborative initiatives have already lead us closer to ALS treatments and a cure. Central to all new collaborations is the people living with ALS.

Neuro Collaborative

The Neuro Collaborative is a partnership between three leading laboratories in California. The synergetic model brings together complementary expertise to advance understanding of ALS and drug development. From sharing information to attracting industry investment, The Neuro Collaborative is an essential initiative that is driving potential therapeutics for ALS quickly toward FDA approval.

Project MinE

Project MinE is an international, large-scale research initiative devoted to discovering genetic causes of ALS and to ultimately find a cure. Project MinE is based on the fact that genes are thought to contribute, directly or indirectly, to many cases of ALS. Many ALS genes have been identified, but researchers suspect that many more, much rarer variants that affect the risk of ALS are awaiting discovery.

Genomic Translation for ALS Care (GTAC)

Genomic Translation for ALS Care (GTAC) is a collaboration with Biogen and Columbia University Medical Center (CUMC) to better understand how different genes contribute to various clinical forms of ALS. This will in turn help researchers design better, more focused clinical trials for the development of more effective treatments. This kind of precision medicine, in which treatment is tailored to each person’s unique genetic makeup, will be effectively applied to ALS.

New York Genome Center - Center for Genomics of Neurodegenerative Diseases (NYGC CGND)

Recent discoveries have indicated that genes may contribute to a much larger percentage of ALS cases than previously thought. Finding these genes and understanding how they work will allow development of new therapeutic approaches.

CReATe Consortium

The Clinical Research in ALS and related disorders for Therapeutic Develoment (CReATe) Consortium is a collaborative effort to foster the discovery and validation of biomarkers relevant to therapy development for people living with ALS and related disorders including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA).